Literature DB >> 27088913

Microenvironmental cues for T-cell acute lymphoblastic leukemia development.

Diana Passaro1, Christine Tran Quang2,3, Jacques Ghysdael2,3.   

Abstract

Intensive chemotherapy regimens have led to a substantial improvement in the cure rate of patients suffering from T-cell acute lymphoblastic leukemia (T-ALL). Despite this progress, about 15% and 50% of pediatric and adult cases, respectively, show resistance to treatment or relapse with dismal prognosis, calling for further therapeutic investigations. T-ALL is an heterogeneous disease, which presents intrinsic alterations leading to aberrant expression of transcription factors normally involved in hematopoietic stem/progenitor cell development and mutations in genes implicated in the regulation of cell cycle progression, apoptosis, and T-cell development. Gene expression profiling allowed the classification of T-ALL into defined molecular subgroups that mostly reflects the stage of their differentiation arrest. So far this knowledge has not translated into novel, targeted therapy. Recent evidence points to the importance of extrinsic signaling cues in controlling the ability of T-ALL to home, survive, and proliferate, thus offering the perspective of new therapeutic options. This review summarizes the present understanding of the interactions between hematopoietic cells and bone marrow/thymic niches during normal hematopoiesis, describes the main signaling pathways implicated in this dialog, and finally highlights how malignant T cells rely on specific niches to maintain their ability to sustain and propagate leukemia.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  T-cell acute lymphoblastic leukemia; leukemic niche; oncogene; signaling; targeted therapy; tumor microenvironment

Mesh:

Year:  2016        PMID: 27088913     DOI: 10.1111/imr.12402

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  11 in total

1.  JNK/AP-1 activation contributes to tetrandrine resistance in T-cell acute lymphoblastic leukaemia.

Authors:  Jun-Ting Liou; Chin-Sheng Lin; Yu-Cheng Liao; Ling-Jun Ho; Shih-Ping Yang; Jenn-Haung Lai
Journal:  Acta Pharmacol Sin       Date:  2017-06-12       Impact factor: 6.150

2.  The CXCR4 Antagonist, AMD3100, Reverses Mesenchymal Stem Cell-Mediated Drug Resistance in Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Shan Wang; Xiaojiao Wang; Sha Liu; Shengnan Zhang; Xudong Wei; Yongping Song; Qingsong Yin
Journal:  Onco Targets Ther       Date:  2020-07-06       Impact factor: 4.147

3.  Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia.

Authors:  Oxana Dobrovinskaya; Georgina Valencia-Cruz; Luis Castro-Sánchez; Edgar O Bonales-Alatorre; Liliana Liñan-Rico; Igor Pottosin
Journal:  Front Pharmacol       Date:  2016-08-31       Impact factor: 5.810

Review 4.  Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia.

Authors:  Deborah Bongiovanni; Valentina Saccomani; Erich Piovan
Journal:  Int J Mol Sci       Date:  2017-09-05       Impact factor: 5.923

5.  Regulation of the Notch-ATM-abl axis by geranylgeranyl diphosphate synthase inhibition.

Authors:  Sherry S Agabiti; Jin Li; Willie Dong; Michael M Poe; Andrew J Wiemer
Journal:  Cell Death Dis       Date:  2019-09-30       Impact factor: 8.469

6.  Overexpression of MiR-506 in Jurkat (Acute T Cell Leukemia) Cell Line.

Authors:  Shaghayegh Rostami Yasuj; Narges Obeidi; Gholamreza Khamisipou; Zeynab Gharehdaghi; Zivar Zangeneh
Journal:  Iran J Pathol       Date:  2020-07-16

7.  Phospho-Specific Flow Cytometry Reveals Signaling Heterogeneity in T-Cell Acute Lymphoblastic Leukemia Cell Lines.

Authors:  Omar Perbellini; Chiara Cavallini; Roberto Chignola; Marilisa Galasso; Maria T Scupoli
Journal:  Cells       Date:  2022-06-29       Impact factor: 7.666

Review 8.  Modeling the human bone marrow niche in mice: From host bone marrow engraftment to bioengineering approaches.

Authors:  Ander Abarrategi; Syed A Mian; Diana Passaro; Kevin Rouault-Pierre; William Grey; Dominique Bonnet
Journal:  J Exp Med       Date:  2018-02-16       Impact factor: 14.307

9.  DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.

Authors:  Yonghan He; Raphael Koch; Vivekananda Budamagunta; Peiyi Zhang; Xuan Zhang; Sajid Khan; Dinesh Thummuri; Yuma T Ortiz; Xin Zhang; Dongwen Lv; Janet S Wiegand; Wen Li; Adam C Palmer; Guangrong Zheng; David M Weinstock; Daohong Zhou
Journal:  J Hematol Oncol       Date:  2020-07-16       Impact factor: 17.388

10.  Post-Irradiation Thymic Regeneration in B6C3F1 Mice Is Age Dependent and Modulated by Activation of the PI3K-AKT-mTOR Pathway.

Authors:  Masaaki Sunaoshi; Benjamin J Blyth; Yi Shang; Chizuru Tsuruoka; Takamitsu Morioka; Mayumi Shinagawa; Mari Ogawa; Yoshiya Shimada; Akira Tachibana; Daisuke Iizuka; Shizuko Kakinuma
Journal:  Biology (Basel)       Date:  2022-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.